Table_1_The C-terminus of NMDAR GluN1-1a Subunit Translocates to Nucleus and Regulates Synaptic Function.doc

NMDARs, the Ca2+ permeable channels, play central roles in synaptic plasticity, brain development, learning, and memory. NMDAR binding partners and associated signaling has been extensively studied in synapse-to-nucleus communications. However, whether NMDARs could directly regulate synapse-to-nucleus communications is largely unknown. Here, we analyze the four alternative splicing of the C-terminus isoforms of GluN1 (1a, 2a, 3a, and 4a), and find that C1 domain of GluN1 is necessary for nuclear localization. Besides, we find that the 10 basic amino acids in C1 domain determine the nuclear localization of GluN1 C-terminus. Further investigating the expression patterns of the full length of GluN1 four isoforms shows that only GluN-1a exhibits the cytoplasmic and nucleus distribution in primary hippocampal neurons. Electrophysiological analyses also show that over-expression of GluN1 C-terminus without C1 domain doesn't affect synaptic transmission, whereas GluN1 C-terminus containing C1 domain potentiates NMDAR-mediated synaptic transmission. Our data suggested that the 10 basic amino acids in C1 domain determine translocation of GluN1 C-terminus into nucleus and regulate synaptic transmission.</p

sj-pdf-2-imr-10.1177_03000605211047779 - Supplemental material for A rare case of type II negative pressure pulmonary edema following extraction of inhaled peanuts in a 21-month-old boy

Supplemental material, sj-pdf-2-imr-10.1177_03000605211047779 for A rare case of type II negative pressure pulmonary edema following extraction of inhaled peanuts in a 21-month-old boy by Qin Li and Liang Zhou in Journal of International Medical Research</p

sj-pdf-1-imr-10.1177_03000605211047779 - Supplemental material for A rare case of type II negative pressure pulmonary edema following extraction of inhaled peanuts in a 21-month-old boy

Supplemental material, sj-pdf-1-imr-10.1177_03000605211047779 for A rare case of type II negative pressure pulmonary edema following extraction of inhaled peanuts in a 21-month-old boy by Qin Li and Liang Zhou in Journal of International Medical Research</p

Image2_Comparison of current treatment strategy for osteonecrosis of the femoral head from the perspective of cell therapy.TIFF

Aims: The purpose of our study is to compare the effects of core decompression (CD) and bone grafting (BG) on osteonecrosis of the femoral head (ONFH). And evaluate the efficacy of CD based on cell therapy to provide guidance for the dose and number of cells.Methods: We searched PubMed, Embase, and the Cochrane Library between 2012 and 2022, with keywords including “osteonecrosis of the femoral head”, “core decompression” and “bone grafting”. We selected comparative studies of CD and BG, and the comparison of CD combined with bone marrow (BM) transplantation and CD alone. Changes in hip pain were assessed by VAS, hip function were assessed by HHS and WOMAC, and THA conversion rate was used as an evaluation tool for femoral head collapse. From these three aspects, the dose of bone marrow and the number of cells transplantation were subgroup analyzed.Results: Eleven studies were used to compare the efficacy of CD and BG. There was no significant difference in HHS, and the THA conversion rate of BG was significantly lower than that of CD. Thirteen CD studies based on cell therapy were included in the meta-analysis. Bone marrow aspiration concentrate (BMAC) can significantly improve VAS (mean difference (MD), 10.15; 95% confidence intervals (CI) 7.35 to 12.96, p 9 magnitude in VAS score were lower.Conclusion: In general, there is no consensus on the use of BG in the treatment of ONFH. The enhancement of cell-based CD procedure shows promising results. Using 20 mL BMAC and 109 magnitude BMMC is likely to achieve better results.</p

Image3_Comparison of current treatment strategy for osteonecrosis of the femoral head from the perspective of cell therapy.TIFF

Aims: The purpose of our study is to compare the effects of core decompression (CD) and bone grafting (BG) on osteonecrosis of the femoral head (ONFH). And evaluate the efficacy of CD based on cell therapy to provide guidance for the dose and number of cells.Methods: We searched PubMed, Embase, and the Cochrane Library between 2012 and 2022, with keywords including “osteonecrosis of the femoral head”, “core decompression” and “bone grafting”. We selected comparative studies of CD and BG, and the comparison of CD combined with bone marrow (BM) transplantation and CD alone. Changes in hip pain were assessed by VAS, hip function were assessed by HHS and WOMAC, and THA conversion rate was used as an evaluation tool for femoral head collapse. From these three aspects, the dose of bone marrow and the number of cells transplantation were subgroup analyzed.Results: Eleven studies were used to compare the efficacy of CD and BG. There was no significant difference in HHS, and the THA conversion rate of BG was significantly lower than that of CD. Thirteen CD studies based on cell therapy were included in the meta-analysis. Bone marrow aspiration concentrate (BMAC) can significantly improve VAS (mean difference (MD), 10.15; 95% confidence intervals (CI) 7.35 to 12.96, p 9 magnitude in VAS score were lower.Conclusion: In general, there is no consensus on the use of BG in the treatment of ONFH. The enhancement of cell-based CD procedure shows promising results. Using 20 mL BMAC and 109 magnitude BMMC is likely to achieve better results.</p

Results of meta-analysis for 2q35-rs13387042 polymorphism and BC risk.

a<p>Q statistic test used to assess the heterogeneity in subgroups.</p>b<p>Q statistic test used to assess the heterogeneity between subgroups.</p

Image1_Comparison of current treatment strategy for osteonecrosis of the femoral head from the perspective of cell therapy.TIFF

Aims: The purpose of our study is to compare the effects of core decompression (CD) and bone grafting (BG) on osteonecrosis of the femoral head (ONFH). And evaluate the efficacy of CD based on cell therapy to provide guidance for the dose and number of cells.Methods: We searched PubMed, Embase, and the Cochrane Library between 2012 and 2022, with keywords including “osteonecrosis of the femoral head”, “core decompression” and “bone grafting”. We selected comparative studies of CD and BG, and the comparison of CD combined with bone marrow (BM) transplantation and CD alone. Changes in hip pain were assessed by VAS, hip function were assessed by HHS and WOMAC, and THA conversion rate was used as an evaluation tool for femoral head collapse. From these three aspects, the dose of bone marrow and the number of cells transplantation were subgroup analyzed.Results: Eleven studies were used to compare the efficacy of CD and BG. There was no significant difference in HHS, and the THA conversion rate of BG was significantly lower than that of CD. Thirteen CD studies based on cell therapy were included in the meta-analysis. Bone marrow aspiration concentrate (BMAC) can significantly improve VAS (mean difference (MD), 10.15; 95% confidence intervals (CI) 7.35 to 12.96, p 9 magnitude in VAS score were lower.Conclusion: In general, there is no consensus on the use of BG in the treatment of ONFH. The enhancement of cell-based CD procedure shows promising results. Using 20 mL BMAC and 109 magnitude BMMC is likely to achieve better results.</p

Characteristics of studies included in a meta-analysis of the association between 2q35-rs13387042 and BC.

<p>NA: not applicable.</p

Quantitative Assessment of 2q35-rs13387042 Polymorphism and Hormone Receptor Status with Breast Cancer Risk

<div><p>Background</p><p>The association between rs13387042 polymorphism on 2q35 and breast cancer (BC) has been widely evaluated since it was first identified through genome-wide association approach. However, the results have been inconclusive. To investigate this inconsistency, we performed a meta-analysis of all available studies dealing with the relationship between the 2q35-rs13387042 polymorphism and BC.</p><p>Methods</p><p>Databases including MEDLINE, PubMed, EMBASE, ISI web of science and CNKI (China National Knowledge Infrastructure) were searched to find relevant studies. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of association. The random-effects model was applied, addressing heterogeneity and publication bias.</p><p>Results</p><p>A total of 24 articles involving 99,772 cases and 164,985 controls were included. In a combined analysis, the summary per-allele odds ratio (OR) for BC of 2q35-rs13387042 polymorphism was 1.13 (95% CI: 1.11–1.16; P<10⁻⁵). Significant associations were also detected under co-dominant, dominant and recessive genetic models. In the subgroup analysis by ethnicity, significantly increased risks were found in Asians, Caucasians and Hispanic whites for the polymorphism in all comparisons; whereas no significant associations were found among Africans. In addition, we find 2q35-rs13387042 polymorphism conferred significantly risks for both ER-positive and ER-negative tumors. Furthermore, significant associations were also detected both in PR–positive and PR–negative cancer.</p><p>Conclusions</p><p>Our findings demonstrated that rs13387042-A allele is a risk-conferring factors for the development of BC, especially in Asians, Caucasians and Hispanic whites.</p></div

Forest plot for association of 2q35-rs13387042 polymorphism and BC risk.

<p>Forest plot for association of 2q35-rs13387042 polymorphism and BC risk.</p